JPM 9.64ATD.TO 0.76MTD 11.7401CRWD -30.31AMD -22.52AVGO -60.825TVE.TO 0.37
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.72
+0.38 (1.48%)
as of Jun 4, 2026, 7:03:20 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY

Pfizer Inc(PFE)

Aug 16, 2004
Has the highest yield and lowest PE that it has had for many many years. Good product pipeline. The stocks and biotechnology will do well in this decade. Hold for 1 to 2 years.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$31.40

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 28, 2004
It has not been a good month for pharmaceuticals. US election is causing some uncertainty which has put some pressure on the stock. A world-class company. Good revenue growth. Looking at about 13 X 2005 earnings.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$31.62

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 27, 2004
An excellent company, but there are other places they would rather invest in, such as Johnson and Johnson. Under attack by generic products.
Photo of Ian NakamotoIan Nakamoto
No
Unlock Rating
$32.10

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 20, 2004
Sector analysis indicates more distribution than new accumulation so in general, pharmaceuticals are underperforming. They were treated as defensive holdings during the bear market. Since then, earnings haven't been strong enough to sustain valuation.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$32.33

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 19, 2004
A great name for a long-term holding. A more conservative guidance brought the stock down. Drug stocks tend to do best when interest rates are rising.
Photo of Norman LevineNorman LevineUnlock Rating
$32.11

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 12, 2004
Like this sector. Good name. Growth potential is good.
Photo of Ray SteeleRay Steele
No
Unlock Rating
$33.63

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 09, 2004
Likes the quality stocks, especially the health related ones.
Photo of Lou HollandLou Holland
Owned
Unlock Rating
$34.00

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 04, 2004
One of the world's best drug companies and as cheap as it's been in the long, long time.
Photo of Lou HollandLou Holland
Owned
Unlock Rating
$35.62

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

May 25, 2004
Large, US pharmaceutical stocks typically do well in a rising interest rate environment.
Photo of Neil WickhamNeil WickhamUnlock Rating
$34.74

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 14, 2004
Photo of Gene HensslerGene Henssler
Owned
Unlock Rating
$35.53

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 13, 2004
A lot of international sales. Have one of the strongest pipelines. A great core holding.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$35.40

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Apr 29, 2004
(Top Pick March 29/04. Up 2.5%.) Lots of upside potential.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$35.57

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 07, 2004
On his watch list. Have a very strong product offering. High quality management. Probably the best drug portfolio and retail pipeline.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$35.67

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 02, 2004
The inclusion in the DOW is significant and we'll give it an upward bias. One of the best pharmaceutical companies in the world. There is competition and drug pipelines are a little tougher. A little expensive.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$36.00

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Apr 01, 2004
Is going to be listed in the Dow on Monday which will have a positive impact for the short term. As a multiple in the low 20's. Has decent growth, but it's less than the multiple. Probably reasonably valued and any upside would make it overvalued.
Photo of Bruce Campbell (1)Bruce Campbell (1)Unlock Rating
$35.59

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 721 to 735 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BHP -2.05$88.8
TA.TO -2.08$18
V 7.75$320.15
TOU.TO -0.12$65.42
NVO 1.79$43.79

Today's Top Picks

JPM 9.64$310.49
ATD.TO 0.76$80.79
MTD 11.74$1181.0601
CRWD -30.31$717.3
AMD -22.52$520

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.605$105.255
BB.TO 0.3$14.4

Most Recent Experts

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bryn Talkington

Bryn Talkington

Requisite Capital Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica